Bartlett & Co. LLC Acquires 10,740 Shares of Gilead Sciences, Inc. (GILD)
Bartlett & Co. LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 302,079 shares of the biopharmaceutical company’s stock after buying an additional 10,740 shares during the period. Bartlett & Co. LLC’s holdings in Gilead Sciences were worth $24,474,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of the business. Whittier Trust Co. of Nevada Inc. increased its stake in shares of Gilead Sciences by 1.0% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 102,715 shares of the biopharmaceutical company’s stock worth $8,322,000 after purchasing an additional 996 shares during the last quarter. Whittier Trust Co. increased its stake in shares of Gilead Sciences by 3.9% during the 3rd quarter. Whittier Trust Co. now owns 169,995 shares of the biopharmaceutical company’s stock worth $13,773,000 after purchasing an additional 6,459 shares during the last quarter. APG Asset Management N.V. increased its stake in shares of Gilead Sciences by 4.0% during the 3rd quarter. APG Asset Management N.V. now owns 5,754,214 shares of the biopharmaceutical company’s stock worth $466,206,000 after purchasing an additional 222,200 shares during the last quarter. DORCHESTER WEALTH MANAGEMENT Co increased its stake in shares of Gilead Sciences by 1.5% during the 3rd quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 69,658 shares of the biopharmaceutical company’s stock worth $5,644,000 after purchasing an additional 1,048 shares during the last quarter. Finally, Douglas Lane & Associates LLC increased its stake in shares of Gilead Sciences by 17.1% during the 3rd quarter. Douglas Lane & Associates LLC now owns 11,725 shares of the biopharmaceutical company’s stock worth $950,000 after purchasing an additional 1,715 shares during the last quarter. Hedge funds and other institutional investors own 75.94% of the company’s stock.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $74.98, for a total value of $5,498,508.34. Following the completion of the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at approximately $230,196,023.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold a total of 494,999 shares of company stock valued at $37,404,139 in the last three months. Insiders own 1.30% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.75 EPS. equities research analysts expect that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.66%.
GILD has been the topic of several recent analyst reports. BMO Capital Markets restated a “hold” rating and set a $82.00 price objective on shares of Gilead Sciences in a research note on Friday, October 20th. J P Morgan Chase & Co set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Vetr raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price for the company in a report on Wednesday, September 6th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $83.00 target price (up previously from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $85.03.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/bartlett-co-llc-acquires-10740-shares-of-gilead-sciences-inc-gild/1775627.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.